Showing 2040 results
-
Ad hoc release /Basel, June 1, 2018 - Novartis AG ("Novartis") today announced the completion of the divestment to GlaxoSmithKline PLC ("GSK") of its 36.5 percent stake in a consumer healthcare joint venture (JV)…
-
Ad hoc release /
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
Ad hoc announcement pursuant to Art. 53 LRQ1 net sales grew +11% (cc1, +10% USD) with core operating income up +22% (cc, +16% USD)Key growth drivers continued strong sales momentum including Entresto… -
Press release /New Cosentyx® (secukinumab) label to include dosing flexibility up to 300 mg, based on clinical response, and 24-week structural data with subcutaneous (sc) regimens[1] Cosentyx inhibits…
-
Press release /New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16…
-
Press release /Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines1 Currently…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance from…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Ligelizumab, a high-affinity anti-IgE antibody, demonstrated superiority compared with placebo at Week 12 in Phase III PEARL 1 and…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s…
-
Press release /V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C) goals early with reduced muscle pain1 85%…
-
Clinical Trials /